Objective: To verify the accuracy and effectiveness of Goldengate high-throughput deafness gene chip in detecting the patients with enlarged vestibular aqueduct syndrome(EVAS), and to provide a reference for genetic detection strategy of EVAS. Methods: From August 2016 to February 2018, 15 patients with EVAS and 60 normal controls were detected by Goldengate high-throughput deafness detection chip developed by our team, and the results were verified by Sanger sequencing. SLC26A4 gene sequencing was carried out in all the patients with EVAS. Results: 12/15 of patients with EVAS were detected mutations of SLC26A4 gene. Nine mutations were detected by chip detection and SLC26A4 gene direct sequencing, seven of which were detected by both methods. The chip could detect 93.33%(28/30) of the allele information provided by SLC26A4 gene direct sequencing. In addition to SLC26A4 gene, mutations of GJB2, PCDH15, TMC1, MYO6 and mitochondrial genes were detected in 15 patients with EVAS. These results were verified by Sanger sequencing. Conclusion: Goldengate high-throughput deafness gene chip possesses the traits of wide coverage and high accuracy, which can be used as a preliminary detection method for patients with EVAS.
目的： 将Goldengate高通量耳聋基因芯片应用于大前庭水管综合征患者，验证芯片的准确性及有效性，为制定更加详细的大前庭水管综合征遗传检测策略提供参考。 方法： 2016年8月至2018年2月利用本研究团队研发的Goldengate高通量耳聋检测芯片，检测15例确诊为大前庭水管综合征耳聋患者及60例健康人对照样本，并利用Sanger测序法验证芯片检测结果。所有大前庭水管综合征患者均进行SLC26A4基因测序，并与芯片结果进行对比分析。 结果： 12/15患者通过芯片检测出SLC26A4基因突变，通过芯片检测和SLC26A4基因直接测序共检出9种突变，其中7种突变被两种方法均检出，该芯片可检测出SLC26A4基因直接测序法所提供的等位基因信息的93.33%（28/30）。除SLC26A4基因以外，15例大前庭水管综合征患者通过芯片还同时检测出GJB2、PCDH15、TMC1、MYO6以及线粒体基因的突变，并均经过Sanger测序法得到验证。 结论： Goldengate高通量耳聋基因芯片具有检测覆盖广、准确性高等特点，可作为大前庭水管综合征患者的初步检测手段。.